GlassScriptPhysician profile
Kaylan Lancaster
NPI 1689158446
$6,711.77
in general payments reported to CMS, 2019-2025
38 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,746 · 2022: $1,566 · 2023: $1,330 · 2024: $995 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,399.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,052.85 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $666.36 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.21 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $603.10 | 2021-2023 | Xarelto |
| Lilly USA, LLC | $550.31 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $457.90 | 2021-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $441.97 | 2022-2025 | |
| Amgen INC. | $345.48 | 2021-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $249.74 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $207.83 | 2021-2025 | Trintellix |
| Abbvie INC. | $202.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $133.31 | 2022-2024 | Trelegy Ellipta, Nucala |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.65 | 2021-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $112.68 | 2021-2023 | Verquvo, Belsomra |
| Exact Sciences Corporation | $107.71 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaylan Lancaster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.